Showing 5601-5610 of 5771 results for "".
- Bausch + Lomb Receives FDA 510(k) Clearance for Boston Scleral Lens Casehttps://modernod.com/news/bausch-lomb-receives-fda-510k-clearance-for-boston-scleral-lens-case/2480229/Bausch + Lomb announced that it has received 510(K) clearance from the FDA for the Boston scleral lens case, a storage case developed specifically for scleral lenses. The case is designed to hold lenses up to 23.5 millimeters in diameter and up to 10.0 millimeters in sagittal depth. The Boston sc
- Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018https://modernod.com/news/data-from-biotimes-opregen-and-retinal-restoration-programs-to-be-presented-at-arvo-2018/2480231/BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii. The scheduled times (note
- Optimo Medical Receives CE Mark for Optimeyes Surgical Planning Toolhttps://modernod.com/news/optimo-medical-receives-ce-mark-for-optimeyes-surgical-planning-tool/2480233/Switzerland-based Optimo Medical AG announced that it has received CE Mark for Optimeyes as a Class 2b medical device. The Optimeyes software predicts in a patient-specific way the influence of physical interventions in the cornea, allowing it to simulate and evaluate treatment results in
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Aerie Pharmaceuticals Joins the ASCRS Foundation in Raising Funds to Provide Eye Care for the World’s Neediest Patientshttps://modernod.com/news/aerie-pharmaceuticals-joins-the-ascrs-foundation-in-raising-funds-to-provide-eye-care-for-the-worlds-neediest-patients/2480240/Aerie Pharmaceuticals announced that it is matching, $1 for $1, the first $25,000 donated by attendees at the 2018 ASCRS-ASOA Annual Meeting, being held in Washington DC, from April 13-17, to the ASCRS Foundation’s charitable eye care programs. “The ASCRS Foundation is amplifying a long tr
- Alcon Launches New Technological Enhancements to the LenSx Laserhttps://modernod.com/news/alcon-launches-new-technological-enhancements-to-the-lensx-laser/2480242/Alcon will introduce new technological enhancements to the LenSx Laser at the American Society of Cataract and Refractive Surgery (ASCRS) 2018 annual meeting taking place April 13-17 in Washington, DC. The latest enhancements will provide new indications for use of the LenSx Laser during cataract
- Glaukos Files Patent Infringement Lawsuit Against Ivantishttps://modernod.com/news/glaukos-files-patent-infringement-lawsuit-against-ivantis/2480243/Glaukos announced that it has filed a patent infringement lawsuit against Ivantis in the U.S. District Court for the Central District of California, Southern Division. The lawsuit alleges that Ivantis’ Hydrus Microste
- Zeiss Presents Diagnostic and Surgical Advancements at ASCRShttps://modernod.com/news/zeiss-presents-diagnostic-and-surgical-advancements-at-ascrs/2480244/Zeiss will present its latest ophthalmic diagnostic and surgical advancements at the 2018 American Society of Cataract and Refractive Surgery’s Annual Meeting taking place April 13-17 in Washington DC. Zeiss will also be hosting
- Alcon Introduces Preloaded Delivery System for the CyPass Micro-Stenthttps://modernod.com/news/alcon-introduces-preloaded-delivery-system-for-the-cypass-micro-stent/2480245/Alcon has announced the launch of the CyPass Ultra System designed to streamline the process of loading the CyPass Micro-Stent, a microinvasive glaucoma surgery (MIGS) device indicated for use in adult patients with mild-to-moderate primary open-angle glaucoma undergoing cataract surgery. The new
- Omidria Added to Veterans Health Administration National Formularyhttps://modernod.com/news/omidria-added-to-veterans-health-administration-national-formulary/2480248/Omeros announced that the Veterans Administration (VA) has added Omidria (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.